NetworkNewsBreaks – Why Skinvisible, Inc. (SKVI)
Post# of 47
(Total Views: 219)
Posted On: 10/12/2017 7:18:54 PM
NetworkNewsBreaks – Why Skinvisible, Inc. (SKVI) is Worth Watching in a $65B Market
Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is an R&D company offering its patented Invisicare® technology, which can be used to revitalize or create new medical or skincare products, thus enabling companies that license Skinvisible’s formulations to sell their own patented products and ward off generic rivals. A high-performance topical and transdermal delivery system, Invisicare enhances the delivery of drugs and other ingredients to and through the skin utilizing Skinvisible’s innovative formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. An article discussing this reads: “A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of ‘gold standard’ dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is an R&D company offering its patented Invisicare® technology, which can be used to revitalize or create new medical or skincare products, thus enabling companies that license Skinvisible’s formulations to sell their own patented products and ward off generic rivals. A high-performance topical and transdermal delivery system, Invisicare enhances the delivery of drugs and other ingredients to and through the skin utilizing Skinvisible’s innovative formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. An article discussing this reads: “A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of ‘gold standard’ dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Skinvisible, Inc. (SKVI) Stock Research Links
Scroll down for more posts ▼